Marburg Virus Hemorrhagic Fever (Filoviruses)
Overview
Plain-Language Overview
Marburg Virus Hemorrhagic Fever (Filoviruses) is a rare but severe illness caused by a virus that affects the body's blood vessels and immune system. It primarily targets the vascular system, leading to widespread bleeding and damage to multiple organs. The disease starts with sudden symptoms like fever, muscle pain, and weakness, and can quickly progress to severe bleeding both internally and externally. This bleeding is due to the virus damaging the lining of blood vessels, causing them to leak. The infection can affect many parts of the body, including the liver, kidneys, and brain, leading to serious complications. Because it spreads through contact with infected bodily fluids, it can cause outbreaks in communities. The illness is life-threatening and requires urgent medical attention.
Clinical Definition
Marburg Virus Hemorrhagic Fever (Filoviruses) is a highly fatal viral hemorrhagic fever caused by the Marburg virus, a member of the Filoviridae family. The core pathology involves viral replication in monocytes, macrophages, and endothelial cells, leading to endothelial damage, coagulopathy, and a systemic inflammatory response. This results in widespread vascular leakage, hemorrhage, and multi-organ failure. Transmission occurs through direct contact with infected bodily fluids or contaminated materials. The disease has an incubation period of 2 to 21 days, followed by an acute febrile phase with symptoms such as high fever, severe headache, myalgia, and gastrointestinal symptoms. Progression to hemorrhagic manifestations and shock is common in severe cases. The high mortality rate and potential for outbreaks make it a significant public health concern.
Inciting Event
Initial zoonotic transmission from fruit bats or infected animals to humans through contact with blood or secretions.
Human-to-human transmission via direct contact with blood, secretions, or contaminated surfaces during outbreaks.
Exposure to contaminated medical equipment or needles in healthcare settings can initiate infection.
Handling or consumption of infected bushmeat serves as an inciting event in many cases.
Latency Period
The incubation period ranges from 2 to 21 days, typically around 5 to 10 days before symptom onset.
Symptoms usually develop within 1 week after exposure to the virus.
Latency is influenced by the viral load and route of exposure.
Diagnostic Delay
Early symptoms are nonspecific and flu-like, often leading to misdiagnosis as malaria or typhoid fever.
Limited access to specialized laboratory testing such as RT-PCR in endemic regions delays confirmation.
Low clinical suspicion due to rarity and similarity to other tropical infections contributes to delayed diagnosis.
Fear of isolation and stigma may cause patients to delay seeking medical care.
Clinical Presentation
Signs & Symptoms
High fever, severe headache, and myalgia during the initial febrile phase
Severe malaise and prostration with rapid progression
Gastrointestinal symptoms including nausea, vomiting, diarrhea, and abdominal pain
Hemorrhagic manifestations such as bleeding from mucous membranes and injection sites
Multi-organ failure signs including renal failure and respiratory distress
History of Present Illness
Initial presentation includes sudden onset of high fever, severe headache, and malaise.
Progression to myalgia, vomiting, diarrhea, and abdominal pain occurs within days.
Development of hemorrhagic signs such as petechiae, ecchymoses, mucosal bleeding, and bleeding from venipuncture sites follows.
Patients often experience shock, multi-organ dysfunction, and altered mental status in severe cases.
Symptom progression is rapid, with deterioration typically occurring within 7 to 10 days.
Past Medical History
Previous exposure to endemic areas or contact with known cases increases risk.
History of immunosuppression may worsen disease severity but is not a prerequisite.
No specific chronic illnesses are required for infection but comorbidities may influence outcome.
Prior vaccination against other hemorrhagic fevers does not confer protection against Marburg virus.
Family History
No known heritable genetic predisposition or familial syndromes are associated with Marburg virus infection.
Clusters of cases may occur within families due to close contact transmission during outbreaks.
Family members of infected patients are at high risk due to shared exposure and caregiving roles.
Physical Exam Findings
Petechiae and purpura due to widespread hemorrhage and thrombocytopenia
Conjunctival injection and mucosal bleeding including bleeding gums
Hypotension and signs of shock from vascular leakage and fluid loss
Hepatomegaly and splenomegaly reflecting systemic viral involvement
Neurologic signs such as confusion or seizures in severe cases
Diagnostic Workup
Diagnostic Criteria
Diagnosis of Marburg Virus Hemorrhagic Fever is established by detecting the Marburg virus in blood or tissue samples using reverse transcription polymerase chain reaction (RT-PCR) or viral culture. Serologic tests detecting IgM and IgG antibodies can support diagnosis but are less useful early in infection. Clinical suspicion arises in patients with compatible symptoms and epidemiologic risk factors such as exposure to endemic areas or contact with infected individuals. Laboratory findings often include thrombocytopenia, elevated liver enzymes, and evidence of coagulopathy. Confirmatory diagnosis relies on molecular detection of viral RNA or isolation of the virus.
Pathophysiology
Key Mechanisms
Viral replication in monocytes, macrophages, and dendritic cells leads to widespread dissemination of the Marburg virus.
Endothelial cell infection causes vascular damage and increased permeability resulting in hemorrhagic manifestations.
Dysregulated immune response with massive release of proinflammatory cytokines contributes to systemic inflammatory response syndrome (SIRS).
Coagulopathy due to consumption of clotting factors and platelets leads to disseminated intravascular coagulation (DIC).
Multiorgan failure results from hypovolemia, shock, and direct viral cytopathic effects on organs such as liver and kidneys.
| Involvement | Details |
|---|---|
| Organs | Liver is a major site of viral replication and damage, causing impaired coagulation factor synthesis and contributing to bleeding. |
Spleen shows extensive necrosis and lymphocyte depletion, weakening immune defense. | |
Kidneys may be affected by hypoperfusion and shock, leading to acute kidney injury. | |
| Tissues | Vascular endothelium is critically involved as viral infection causes endothelial damage leading to hemorrhagic manifestations. |
Lymphoid tissue undergoes necrosis and depletion, impairing immune responses. | |
| Cells | Macrophages are primary target cells for Marburg virus, facilitating viral replication and systemic dissemination. |
Dendritic cells are infected early, leading to impaired antigen presentation and immune dysregulation. | |
Endothelial cells are damaged by viral infection, contributing to vascular leakage and hemorrhage. | |
| Chemical Mediators | Tumor necrosis factor-alpha (TNF-α) is elevated and contributes to systemic inflammation and vascular permeability. |
Interleukin-6 (IL-6) levels increase, promoting the acute phase response and fever. | |
Tissue factor expression is upregulated, triggering disseminated intravascular coagulation. |
Treatments
Pharmacological Treatments
Non-pharmacological Treatments
Provide aggressive supportive care including fluid resuscitation and electrolyte management to prevent shock.
Implement strict infection control measures such as isolation and use of personal protective equipment to prevent transmission.
Use mechanical ventilation if respiratory failure develops.
Administer blood products like platelets and fresh frozen plasma to manage hemorrhagic complications.
Prevention
Pharmacological Prevention
No approved antiviral prophylaxis currently exists for Marburg virus
Experimental vaccines under development may provide future prevention
Post-exposure prophylaxis with monoclonal antibodies is investigational
Non-pharmacological Prevention
Strict barrier nursing and isolation of infected patients to prevent transmission
Use of personal protective equipment (PPE) by healthcare workers
Avoidance of contact with fruit bats and nonhuman primates in endemic regions
Safe burial practices to prevent spread from deceased patients
Community education on transmission routes and early symptom recognition
Outcome & Complications
Complications
Disseminated intravascular coagulation (DIC) leading to widespread bleeding
Multi-organ failure including hepatic, renal, and pulmonary failure
Shock due to vascular leakage and hypovolemia
Secondary bacterial infections from immune compromise
Neurologic complications such as encephalitis or seizures
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Marburg Virus Hemorrhagic Fever (Filoviruses) versus Ebola Virus Disease
Marburg Virus Hemorrhagic Fever (Filoviruses) | Ebola Virus Disease |
|---|---|
Caused by Marburgvirus species | Caused by Ebolavirus species |
Exposure to fruit bats or primates primarily in East Africa | Exposure to fruit bats or primates in West and Central Africa |
Positive RT-PCR for Marburgvirus RNA | Positive RT-PCR for Ebolavirus RNA |
Marburg Virus Hemorrhagic Fever (Filoviruses) versus Lassa Fever
Marburg Virus Hemorrhagic Fever (Filoviruses) | Lassa Fever |
|---|---|
Caused by Marburgvirus, a filovirus | Caused by Lassa virus, an arenavirus |
Exposure to fruit bats or primates in East Africa | Exposure to rodent excreta in West Africa |
Rapid onset with severe hemorrhagic fever and high fatality | Often subacute with gradual onset of hemorrhagic symptoms |
Marburg Virus Hemorrhagic Fever (Filoviruses) versus Yellow Fever
Marburg Virus Hemorrhagic Fever (Filoviruses) | Yellow Fever |
|---|---|
Caused by Marburgvirus, a filovirus | Caused by Yellow fever virus, a flavivirus |
Transmitted by contact with infected bats or primates in Africa | Transmitted by Aedes mosquito bites in tropical Africa and South America |
Severe coagulopathy with widespread hemorrhage without prominent jaundice | Elevated liver enzymes with jaundice and black vomitus |
Marburg Virus Hemorrhagic Fever (Filoviruses) versus Dengue Hemorrhagic Fever
Marburg Virus Hemorrhagic Fever (Filoviruses) | Dengue Hemorrhagic Fever |
|---|---|
Caused by Marburgvirus, a filovirus | Caused by Dengue virus, a flavivirus |
Transmitted by contact with infected bats or primates in Africa | Transmitted by Aedes mosquitoes in tropical and subtropical regions |
Rapid progressive hemorrhagic fever with high mortality | Often biphasic with febrile, critical, and recovery phases |
Marburg Virus Hemorrhagic Fever (Filoviruses) versus Severe Bacterial Sepsis with Disseminated Intravascular Coagulation (DIC)
Marburg Virus Hemorrhagic Fever (Filoviruses) | Severe Bacterial Sepsis with Disseminated Intravascular Coagulation (DIC) |
|---|---|
Negative bacterial cultures; viral RNA detected | Positive blood cultures with bacterial pathogens |
Abrupt onset after exposure to infected animals or body fluids | Sepsis often preceded by localized bacterial infection |
No response to antibiotics; requires supportive care and experimental antivirals | Improves with broad-spectrum antibiotics and supportive care |